Clinical experience with hormonal suppression of ovulation using the sequential method with chlormadinone acetate and mestranol in different dosage. Clinical experience with sequential contraceptives CG 509 and CG 527 (mestranol .08 or .10 mg for 11 days, mestranol and 2 mg chlormadinone acetate for 10 days) in 253 patients (2032 treatment cycles) is reported.  Indications included contraception, menstrual disorders, endometriosis, and functional sterility.  Complete contraceptive efficiency was observed in the study group.  Body temperature curves were monophasic.  Therapeutic results were encouraging, but no long-term conclusions can be drawn.  Side effects included spotting and breakthrough bleeding, allergic and dermatologic reactions, decrease in libido, and weight gain.